Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KEYVIBE-005 in selected advanced solid tumors
2023-505284-36-00Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- Sep 2021
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 15
01
Overview
Phase 2, open-label, single-arm trial of vibostolimab + pembrolizumab, vibostolimab and pembrolizumab in Cervical Cancer (CC), endometrial cancer (EC), head and neck squamous cell carcinoma (HNSCC) and 8 more, sponsored by Merck & Co. Primary endpoints: Objective response rate, Progression-free survival and 3 more. Started Sep 2021; status: completed.
02
Drugs
03
Conditions
Cervical Cancer (CC)endometrial cancer (EC)head and neck squamous cell carcinoma (HNSCC)biliary canceresophageal cancer
Beyond the preview
Go deeper on 2023-505284-36-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-505284-36-00.